98%
921
2 minutes
20
Background: Previous studies showed that urine uranium (U) is associated with asthma prevalence in adults. However, the association between them among the general population is unclear. Therefore, this study aimed to explore this unclear association.
Methods: The data of the participants were collected from the 2007-2016 National Health and Nutrition Examination Survey (NHANES) performed in the United States. Continuous variables with a skewed distribution were analyzed using Ln-transformation. The association between urine U and asthma prevalence was analyzed by multiple regression analysis, and the linear association between them was evaluated by smoothed curve fitting. The subgroup analysis was performed using the hierarchical multivariate regression analysis.
Results: A total of 13,581 participants were included in our analysis. The multivariate regression analysis showed that LnU was independently and positively correlated with asthma prevalence in the general population (OR = 1.12; 95% CI: 1.04-1.20; = 0.002). The subgroup analysis revealed that college graduate or above showed a stronger association between LnU and asthma prevalence (<9th grade: OR = 0.84; 95% CI: 0.61-1.14; 9-11th grade: OR = 1.23; 95% CI: 0.99-1.52; high school grade: OR = 1.00; 95% CI: 0.84-1.19; college: OR = 1.04; 95% CI: 0.91-1.19; ≥college graduate: OR = 1.32; 95% CI: 1.11-1.57; for interaction = 0.0389).
Conclusion: Our research suggested that urinary U levels are positively associated with asthma prevalence among the general population of the United States, and the association is especially strong among people with high levels of education.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10800476 | PMC |
http://dx.doi.org/10.3389/fpubh.2023.1326258 | DOI Listing |
J Eval Clin Pract
September 2025
Pediatric Allergy and Immunology Department, Akdeniz University Hospital, Akdeniz University, Antalya, Türkiye.
Aims And Objectives: To evaluate the efficacy of YoungAsthma, a nurse-led, web-based mHealth intervention on asthma control and self-efficacy among adolescents with asthma utilizing decision tree analysis.
Background: Asthma is a prevalent chronic condition in pediatric populations, necessitating sustained management for optimal disease control.
Design: A randomized controlled clinical trial.
ERJ Open Res
September 2025
Department of Respiratory Diseases, Bichat-Claude Bernard Hospital, Paris, France.
https://bit.ly/4bY6LMc.
View Article and Find Full Text PDFERJ Open Res
September 2025
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Background: Airway obstruction is a characteristic spirometric finding in asthma but the clinical significance of other abnormal spirometric patterns is less well described. We aimed to explore pre- and post-bronchodilator (BD) prevalences and clinical characteristics of preserved ratio impaired spirometry (PRISm), dysanapsis and airflow obstruction with low forced expiratory volume in 1 s (FEV) in children diagnosed with asthma.
Methods: We extracted specialist care data (clinical and spirometry) from the Swedish National Airway Register (n=3301, age 5-17 years).
ERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.
J Asthma Allergy
September 2025
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University Kyoto, Kyoto, Japan.
Background And Purpose: Biologics are crucial for severe asthma treatment, but their high costs pose challenges. Omalizumab (OML) is dosed on the basis of patient-specific factors. The purpose of this study is to clarify the clinical characteristics of severe asthmatics who maintain long-term control on omalizumab including healthcare cost considerations.
View Article and Find Full Text PDF